📊 AWHL Key Takeaways
Is Aspira Women's Health Inc. (AWHL) a Good Investment?
Aspira Women's Health is in severe financial distress with negative stockholders' equity of -4.3M, indicating liabilities exceed assets. The company is burning cash at an alarming rate (-5.1M FCF) while revenue has collapsed 56.4% YoY, generating only 311K in the latest period, making near-term viability questionable.
Aspira Women's Health shows very weak fundamentals, with revenue down sharply year over year, deeply negative operating and net margins, and persistent cash burn relative to a very small revenue base. Although liquidity is not yet exhausted, negative equity, ongoing losses, and poor growth quality indicate a fragile financial position that likely requires external capital or a major operating turnaround.
Why Buy Aspira Women's Health Inc. Stock? AWHL Key Strengths
- Maintains positive current ratio of 1.39x suggesting short-term liquidity remains adequate
- Still holds 3.8M in cash providing runway for operations
- Gross profit positive at 4.5M indicating underlying product economics are present
- Cash of $3.81M provides some near-term operating flexibility
- Current ratio of 1.39x and quick ratio of 1.32x indicate near-term liabilities are still being covered
- Long-term debt is modest in absolute dollars relative to total liabilities
AWHL Stock Risks: Aspira Women's Health Inc. Investment Risks
- Negative stockholders' equity of -4.3M represents technical insolvency with liabilities exceeding assets
- Severe revenue decline of 56.4% YoY with only 311K revenue in latest period indicates collapsing business
- Operating cash burn of -5.0M combined with minimal revenue suggests company will exhaust cash within 9-12 months without turnaround
- Operating losses of -6.6M and net losses of -9.4M demonstrate inability to achieve profitability at current scale
- No insider buying activity in 90 days suggests management lacks confidence
- Revenue declined 56.4% year over year, signaling severe commercial weakness
- Net loss of $9.41M and free cash flow of -$5.06M show the business is far from self-funding
- Negative stockholders equity of -$4.34M reflects balance-sheet stress and limits financial flexibility
Key Metrics to Watch
- Monthly revenue trend and stabilization timeline
- Operating cash burn rate and runway remaining with current cash balance
- Path to profitability or evidence of business stabilization
- Changes in stockholders' equity and debt restructuring plans
- Quarterly revenue stabilization or return to year-over-year growth
- Operating cash burn relative to ending cash balance
Aspira Women's Health Inc. (AWHL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Aspira Women's Health Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AWHL Profit Margin, ROE & Profitability Analysis
AWHL vs Healthcare Sector: How Aspira Women's Health Inc. Compares
How Aspira Women's Health Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aspira Women's Health Inc. Stock Overvalued? AWHL Valuation Analysis 2026
Based on fundamental analysis, Aspira Women's Health Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aspira Women's Health Inc. Balance Sheet: AWHL Debt, Cash & Liquidity
AWHL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aspira Women's Health Inc.'s revenue has shown modest growth of 0% over the 5-year period. The most recent EPS of $-0.93 indicates the company is currently unprofitable.
AWHL Revenue Growth, EPS Growth & YoY Performance
AWHL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3M | -$1.9M | $-0.13 |
| Q2 2025 | $2.4M | -$1.9M | $-0.07 |
| Q1 2025 | $2.2M | -$1.9M | $-0.09 |
| Q3 2024 | $2.2M | -$2.3M | $-0.23 |
| Q2 2024 | $2.4M | -$2.3M | $-0.28 |
| Q1 2024 | $2.2M | -$4.6M | $-0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aspira Women's Health Inc. Dividends, Buybacks & Capital Allocation
AWHL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aspira Women's Health Inc. (CIK: 0000926617)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AWHL
What is the AI rating for AWHL?
Aspira Women's Health Inc. (AWHL) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AWHL's key strengths?
Claude: Maintains positive current ratio of 1.39x suggesting short-term liquidity remains adequate. Still holds 3.8M in cash providing runway for operations. ChatGPT: Cash of $3.81M provides some near-term operating flexibility. Current ratio of 1.39x and quick ratio of 1.32x indicate near-term liabilities are still being covered.
What are the risks of investing in AWHL?
Claude: Negative stockholders' equity of -4.3M represents technical insolvency with liabilities exceeding assets. Severe revenue decline of 56.4% YoY with only 311K revenue in latest period indicates collapsing business. ChatGPT: Revenue declined 56.4% year over year, signaling severe commercial weakness. Net loss of $9.41M and free cash flow of -$5.06M show the business is far from self-funding.
What is AWHL's revenue and growth?
Aspira Women's Health Inc. reported revenue of $311.0K.
Does AWHL pay dividends?
Aspira Women's Health Inc. does not currently pay dividends.
Where can I find AWHL SEC filings?
Official SEC filings for Aspira Women's Health Inc. (CIK: 0000926617) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AWHL's EPS?
Aspira Women's Health Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AWHL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aspira Women's Health Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AWHL stock overvalued or undervalued?
Valuation metrics for AWHL: ROE of N/A (sector avg: 15%), net margin of -3,026.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AWHL stock in 2026?
Our dual AI analysis gives Aspira Women's Health Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AWHL's free cash flow?
Aspira Women's Health Inc.'s operating cash flow is $-5.0M, with capital expenditures of $8.0K. FCF margin is -1,625.7%.
How does AWHL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,026.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.39 (avg: 2).